Daridorexant Synthesis: Key Steps and Chemical Processes
The synthesis of daridorexant involves a multi-step chemical process. A key intermediate in this synthesis is (R)-1-(3-cyano-5-(2-(trifluoromethyl)phenyl)phenyl)-3-(2-oxo-3-(2-((2-(trifluoromethyl)phenyl)amino)ethyl)tetrahydrofuran-2-yl)propan-1-one [1]. This compound's preparation is detailed in patent literature, outlining specific reactions and conditions.
How is the Daridorexant Intermediate Synthesized?
The synthesis of the aforementioned key intermediate typically involves several stages, often beginning with readily available starting materials. One documented synthetic route for this intermediate, as outlined in patent applications, focuses on building the complex molecular structure through a series of controlled chemical transformations. These steps are crucial for achieving the desired stereochemistry and purity of the final active pharmaceutical ingredient [1].
When Does Daridorexant's Patent Protection End?
Information regarding the specific expiry dates of patents covering daridorexant is available through resources like DrugPatentWatch.com [2]. These patents protect the intellectual property associated with the drug's composition, formulation, and manufacturing processes. Understanding patent expiry is vital for anticipating market competition and the potential for generic versions.
What Are the Next Steps After Patent Expiry?
Following the expiry of primary patents, the pathway is generally open for the development and approval of generic versions of daridorexant. This process requires generic manufacturers to demonstrate bioequivalence to the original branded drug and to obtain regulatory approval from agencies such as the U.S. Food and Drug Administration (FDA) [3].
Can Biosimilars Be Developed for Daridorexant?
Daridorexant is a small molecule drug, not a biologic. Therefore, the development pathway for generic versions is distinct from that of biosimilars, which are used for biologic medications [3]. Generic versions of small molecule drugs like daridorexant are typically created through chemical synthesis.
Who Manufactures Daridorexant?
Daridorexant is developed and manufactured by Idorsia Pharmaceuticals [4]. The company holds the primary rights and is responsible for its production and commercialization.
What is the Mechanism of Action for Daridorexant?
Daridorexant functions as a dual orexin receptor antagonist. It blocks the binding of orexin neuropeptides to both OX1R and OX2R receptors in the brain. By inhibiting the wake-promoting signals mediated by orexin, daridorexant promotes sleep [5].
What are the Clinical Trial Results for Daridorexant?
Clinical trials have evaluated daridorexant's efficacy and safety for treating insomnia. Studies have demonstrated its ability to reduce sleep latency and improve sleep maintenance. The safety profile has also been assessed, identifying common adverse events [5].
Sources:
[1] DrugPatentWatch.com. (n.d.). Daridorexant Synthesis Patents. Retrieved from https://drugpatentwatch.com/
[2] DrugPatentWatch.com. (n.d.). Daridorexant Patent Expiry. Retrieved from https://drugpatentwatch.com/
[3] U.S. Food & Drug Administration. (n.d.). Generic Drugs. Retrieved from https://www.fda.gov/drugs/generic-drugs
[4] Idorsia Pharmaceuticals. (n.d.). Daridorexant. Retrieved from https://www.idorsia.com/
[5] DrugBank. (n.d.). Daridorexant. Retrieved from https://go.drugbank.com/